90%Confidence
0Views
FDASource
2026-04-08Date
Summary
Another Class II recall for Teva's Octreotide Acetate (10 mg) from the same Greek manufacturer highlights systemic quality issues at the contract facility. This recurring problem may necessitate finding alternative suppliers, potentially disrupting Teva's supply chain and increasing costs.
Actionable: Investigate Teva's contingency plans for manufacturing and consider the long-term implications on their product portfolio.
AI Confidence: 90%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now